Alessandro Laganà

The paper develops a spatial tri-omics workflow to map genetically distinct myeloma subclones in bone marrow, showing they occupy spatially and biologically distinct niches.

The paper identifies a therapy-driven genomic double-hit (1pCEN LOH and 1q gain) in relapsed/refractory myeloma, associated with poor prognosis and clonal expansion.

This study uses spatial and single-cell transcriptomics to identify niche-specific signaling programs in multiple myeloma that drive progression and immunosuppression.

The paper characterizes immune microenvironment dysregulation in multiple myeloma using single-cell data and links it to disease progression and patient outcomes.

This study uses longitudinal multi-omic profiling to identify immune escape mechanisms and predictors of response in multiple myeloma.

This paper introduces a RAG-based chatbot framework for precision medicine in Multiple Myeloma, integrating genomic data and biomedical literature to provide personalized treatment recommendations.

The paper identifies a three-gene expression signature that predicts response to selinexor in multiple myeloma and glioblastoma.

MiREDiBase is a manually curated database of validated and putative miRNA editing events, including 3,059 sites from 626 pre-miRNAs in humans and three primates.

The paper shows ADAR1 drives Multiple Myeloma progression by editing RNA and causing DNA mutations at editing sites.